California State Teachers Retirement System Raises Position in NewAmsterdam Pharma (NASDAQ:NAMS)

California State Teachers Retirement System raised its holdings in shares of NewAmsterdam Pharma (NASDAQ:NAMS) by 23.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 19,404 shares of the company’s stock after acquiring an additional 3,694 shares during the quarter. California State Teachers Retirement System’s holdings in NewAmsterdam Pharma were worth $499,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently modified their holdings of the company. Frazier Life Sciences Management L.P. lifted its stake in shares of NewAmsterdam Pharma by 23.8% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 15,916,418 shares of the company’s stock valued at $409,052,000 after buying an additional 3,061,224 shares in the last quarter. Bain Capital Life Sciences Investors LLC lifted its stake in shares of NewAmsterdam Pharma by 2.3% during the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 10,719,110 shares of the company’s stock valued at $275,481,000 after buying an additional 245,197 shares in the last quarter. RA Capital Management L.P. lifted its stake in shares of NewAmsterdam Pharma by 9.7% during the 4th quarter. RA Capital Management L.P. now owns 8,845,000 shares of the company’s stock valued at $227,316,000 after buying an additional 781,000 shares in the last quarter. Deerfield Management Company L.P. Series C lifted its stake in shares of NewAmsterdam Pharma by 378.4% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 4,314,340 shares of the company’s stock valued at $110,879,000 after buying an additional 3,412,590 shares in the last quarter. Finally, Woodline Partners LP lifted its stake in shares of NewAmsterdam Pharma by 108.7% during the 4th quarter. Woodline Partners LP now owns 2,430,782 shares of the company’s stock valued at $62,471,000 after buying an additional 1,266,105 shares in the last quarter. Hedge funds and other institutional investors own 89.89% of the company’s stock.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, Director James N. Topper bought 1,135 shares of NewAmsterdam Pharma stock in a transaction dated Wednesday, March 26th. The shares were purchased at an average cost of $22.49 per share, for a total transaction of $25,526.15. Following the acquisition, the director now directly owns 3,013,569 shares in the company, valued at approximately $67,775,166.81. This represents a 0.04% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Insiders own 20.84% of the company’s stock.

NewAmsterdam Pharma Stock Performance

Shares of NASDAQ NAMS opened at $20.50 on Thursday. The company has a market cap of $2.30 billion, a P/E ratio of -10.90 and a beta of -0.03. The firm’s fifty day moving average is $17.99 and its two-hundred day moving average is $20.86. NewAmsterdam Pharma has a 52-week low of $14.06 and a 52-week high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.04). The firm had revenue of $2.98 million for the quarter, compared to analysts’ expectations of $1.46 million. As a group, analysts forecast that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on NAMS. Cantor Fitzgerald began coverage on shares of NewAmsterdam Pharma in a research note on Wednesday, June 4th. They set an “overweight” rating and a $42.00 target price on the stock. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Friday, May 30th. Needham & Company LLC lowered their target price on shares of NewAmsterdam Pharma from $42.00 to $40.00 and set a “buy” rating on the stock in a research note on Thursday, May 8th. Stifel Nicolaus started coverage on shares of NewAmsterdam Pharma in a report on Tuesday. They issued a “buy” rating and a $44.00 price target on the stock. Finally, Scotiabank lifted their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $43.00.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.